2011 Scrip 100: Preferred partners strike gold
This article was originally published in Scrip
Quintiles cleaned up in the first three quarters of 2010. Things would have been different had the CRO not secured a major preferred partner deal, explains Joanne Payne.
You may also be interested in...
Perhaps only a man who inherited an enthusiasm for peptides could, without a trace of irony, cast diabetes drug development as the work of a pastry chef. But for David Solomon, the son of a peptide devotee, mixed metaphors and stretched comparisons are simply the spray thrown up by his unbridled enthusiasm for his chosen trade, that of basketball coach to GLP-1 receptor agonist developer Zealand Pharma.
"How the hell will Glaxo need you? You've only got a few people, they've got about 50,000!"